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Royalactin is a protein with several different potential uses in humans. Research, in
insects and in mammalian cells, has shown that it can accelerate cell division and prevent
apoptosis. The method of action is through the use of the epidermal growth factor receptor,
which is present in humans. Potential use in humans could be to lower cholesterolemic lev-
els in blood, and to elicit similar effects to those seen in bees, e.g., increased lifespan. Mass
production of Royalactin has not been accomplished, though a recent article presented a
Pichia pastoris fermentation and recovery by aqueous two-phase systems at laboratory scale
as a possible basis for production. Economic modelling is a useful tool with which compare
possible outcomes for the production of such a molecule and in particular, to locate areas
where additional research is needed and optimization may be required. This study uses the
BioSolve software to perform an economic analysis on the scale-up of the putative process
for Royalactin. The key parameters affecting the cost of production were located via a sensi-
tivity analysis and then evaluated by Monte Carlo analysis. Results show that if titer is not
optimized the strategy to maintain a low cost of goods is process oriented. After optimization
of this parameter the strategy changes to a product-oriented and the target output becomes
the critical parameter determining the cost of goods. This study serves to provide a frame-
work for the evaluation of strategies for future production of Royalactin, by analyzing the
factors that inﬂuence its cost of manufacture. V C 2015 The Authors Biotechnology Progress
published by Wiley Periodicals, Inc. on behalf of American Institute of Chemical Engineers
Biotechnol. Prog., 000:000–000, 2015
Keywords: royalactin, aqueous two-phase system (ATPS), economic analysis under uncer-
tainty, Monte Carlo simulation, parameter optimization
Introduction
Royal Jelly (RJ) is the source of nutrition needed to
develop bee larvae into future Queen bees. It has a composi-
tion of water (60–70%), proteins (12–15%), sugars (10–
16%), lipids (3–6%), vitamins, and amino acids.
1 It is
responsible for the epigenetic changes seen during the devel-
opment of Queen bees: functional reproductive organs,
weight increase, and longer lifespan.
2 Human consumption
of RJ has been tested with positive results including reduc-
tions in cholesterol and low-density lipoproteins.
3,4
Many of the components of RJ have been isolated, charac-
terized, and tested to determine their individual properties.
For example, trans-10-hydroxy-2-decenoic acid has been
found to possess antibacterial properties,
5 and Royalisin pep-
tide is active against Gram-positive bacteria.
6 From the pro-
teins that compose RJ, around 85% belong to the major RJ
proteins (MRJP) 1–5.
7 Of these proteins, MRJP3 has immu-
noregulatory effects.
8 MRJP1, also known as Royalactin,
stimulates growth of rat hepatocytes and prevents apoptosis,
which suggest action similar to a growth factor.
9 MRJP1 is
also related to the learning ability of bees.
10 More recently,
Royalactin was found to be the only component responsible
for the epigenetic changes that larvae undergo to grow as
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melanogaster. Research found that this protein works
through binding to the epidermal growth factor receptor
(EGFr).
2 This protein is potentially of great interest for
human consumption. Although there is no information on its
stability once ingested, there is evidence of decreased choles-
terol levels after rat consumption,
11 thus suggesting Royalac-
tin can withstand gastric conditions. It also helps to explain
the anticholesterolemic effects of RJ.
3,4 Peptides derived
from MRJP1 after exposure with trypsin where also tested
with positive results in human cell lines.
11
MRJP1, or Royalactin, is a 57 kDa glycoprotein. It repre-
sents approximately 3–4% of total protein in RJ and 30% of
MRJPs.
1 Natural production starts with the collection of RJ.
To obtain Royalactin further puriﬁcation is needed. A well-
trained beekeeper can obtain approximately 500 g of RJ per
season (5–6 months),
12 corresponding to an annual produc-
tion of almost 35 g of Royalactin. An alternative is the use
recombinant organisms. Recombinant production of Royalac-
tin has two main advantages. The ﬁrst one is the potentially
limitless production output and the second one is that
MRJP1 can be produced in a pathogen free environment
(according to GMP outlines). This is currently critical as the
bee population is suffering from colony collapse disorder
which has different causes, but includes viral infection from
several virus strains.
13 Although production in recombinant
systems is problematic. MRJP1 from European Apis melli-
fera has been produced in E. coli with low expression and
the formation of inclusion bodies.
14 In tobacco leaves it has
a low titer.
15 From Eastern Apis cerana, MRJP1 has been
produced in E. coli.
16 Because of its properties, there is how-
ever a great deal of interest in how to achieve mass produc-
tion of MRJP1. Having a constant supply will allow greater
use of the protein in performing assays for food and pharma-
ceutical applications. Recently production in Pichia pastoris
with recovery using aqueous two-phase systems (ATPS) has
been reported
17 as the ﬁrst attempt to create a bioprocess for
the production and recovery of Royalactin.
When designing a bioprocess, it is important to consider
possible scenarios that can occur during development. Bio-
process modelling provides a powerful tool to generate a vir-
tual bioprocess, where input parameters, obtained by
research, may be used to obtain an estimate of the cost of
generating product. Further, use of model-based techniques
can reduce the number of experiments and determine where
attention should be focused resulting in reduction of costs,
time, and improving decision making.
18,19 An additional
advantage of using modeling is the incorporation of the
uncertainties inherent in any bioprocess: changes in produc-
tion titer, downstream processing yield (DSP), material costs,
desired production levels, personnel salary, etc.
19 This allows
the bioprocess engineer to quantify how the production cost
varies, and to include the probabilistic nature of these varia-
tions when making estimates. This area has gained attention
recently, including comparison of the cost of using stainless
steel or single-use equipment,
20 analysis of the impact that
different pooling strategies have in perfusion cultures
21 and
an evaluation of the potential of batch and continuous cell
culture technologies.
22 All these publications identify the
best use of technologies and techniques to decrease the cost
of production per gram of desired product (cost of goods per
gram, CoG/g) without the need to perform extensive experi-
ments, hence saving time by focusing research effort.
Different types of software have been created for biopro-
cess simulation,
23,24 including BioSolve (Biopharm Services,
Chesham, Buckinghamshire, U.K.), SimBioPharma, Aspen,
etc. This software is an Excel-based modelling tool that
takes into account indirect and direct operating costs. This
software allows rapid model construction and has the advant-
age that the costs of equipment and supplies are collected
directly from the supplier, which saves time and means that
the user can rely on the veracity of the data.
This paper focuses on performing an economic analysis of
a bioprocess for the recovery of Royalactin based on the
reported production by Pichia pastoris and use of ATPS.
17
This study will focus only on the manufacture of Royalactin.
Business related factors were not considered (i.e., product
cost, target market, storage, cooling, transportation, etc.). It
will study the effect that optimizing a single parameter can
have on the CoG/g. For this, a base scale-up scenario will be
designed, from which process parameters will be ranked
according to their impact on the CoG/g. A series of Monte
Carlo simulations will then be performed in order to incorpo-
rate uncertainties inherent in the bioprocess design and hence
obtain data on how the CoG/g is distributed. Finally, the
simulation approach will be used to develop a proposal on
how to achieve a low CoG/g in order to maximize proﬁt.
Model Set-Up and Deterministic Analysis
This section will explain the construction of the base sce-
nario used to design the bioprocess for the production and
recovery of Royalactin. First, the sequence of unit operations
was proposed following literature,
17 from it the titer
(0.24260.134 g/L) and ATPS recovery yield (95.861.1%)
were also obtained. It was decided to design the bioprocess
only analyzing ATPS, as it is the only unit operation for which
there is evidence that selective recovery of Royalactin is possi-
ble. The bioprocess is presented as a ﬂowchart in Figure 1.
To determine the size of the bioprocess unit operations a
desired target output has to be proposed. Data have shown
that human consumption of Royalactin can decrease choles-
terol,
11 but also can increase the rate of cell division and
prevent cell death.
9 A potential vehicle for the distribution
of Royalactin is in a sports beverage, especially in a recov-
ery drink, for the prevention of muscle loss and increased
repair. We used this as the bioprocess target output. Accord-
ing to the literature,
25 one top selling brand of recovery
drinks accounts for 4 billion litres per year globally (nearly
50% of the market share in 2011), with the main competitor
brand selling a little over 2%.
26 Taking into account the
entry barriers to existing markets, it was decided to design
the bioprocess conservatively to capture a 0.5% of the mar-
ket share of this main competitor (0.0128% of the total mar-
ket share). The ﬁnal decision to estimate the annual
production is the concentration in each product, it was ﬁxed
at 50 mg/L. This value was obtained from analyzing Roya-
lactin doses to different organisms,
2,9 including human,
3,4
and taking the half of the lower concentration used.
Labor level was an important parameter to establish.
Labor should be between 10 and 15% of the production
cost,
19 the number of employees was assigned to be on 13%.
The operator wage was set according to the current wages in
the United Kingdom.
27 Quality control (QC) costs were
modiﬁed from the default values assumed by BioSolve, since
this software assumes QC costs are based upon monoclonal
antibody (Mab) production which is a far more exacting
2 Biotechnol. Prog., 2015, Vol. 00, No. 00process of manufacture. A feature of BioSolve is the large
library of equipment and materials which facilitates rapid
economic analysis. Costs of the material that are not avail-
able can be input by the user. For this paper, the only inputs
were recipes for media and buffer, particularly for those dur-
ing fermentation and recovery by ATPS.
After setting up the model, an initial estimate of CoG/g
was obtained as the "Base Case Scenario". The CoG/g for
this was of US$ 843.
BioSolve also has the capacity of showing the breakdown
of the CoG/g. For the Base Case Scenario this is shown in
Figure 2. Here it can be seen that the main contribution to
the costs comes from the capital, followed by the consum-
ables (Figure 2a). The consumables costs are in turn
dominated by the ultraﬁltration/diaﬁltration (UF/DF) step
(Figure 2b). This is because of the large quantities of materi-
als needed to perform the ATPS operation which the UF/DF
step must subsequently process.
Identiﬁcation of Uncertainties/Sensitivity Analysis
In the real world, parameters like titer, process recovery
yield, target output, materials cost and operator wages can
all change. All affect the CoG/g to some extent, but some
have a bigger inﬂuence than others. It is important to deter-
mine which are the key parameters in order to develop a
strategy to control them in order to reduce CoG/g. To iden-
tify these parameters a sensitivity analysis was performed, in
which a group of process parameters were increased and
decreased systematically to analyze the effects on the CoG/
g. The parameters used were selected based on the litera-
ture.
20,21,28 Table 1 presents these parameters, along with the
corresponding values for a "Worst Case Scenario" and a
"Best Case Scenario".
For the fermentation titer and DSP yield the range of val-
ues was set by the mean plus and minus one standard devia-
tion.
14 Materials costs are typically reported to change in a
range of 625%,
20,21 and this was adopted in the current
study. The 25% change in material costs was applied to a
subset of the dominant consumables which, for this process,
are the fermentation media (buffered glycerol–complex
medium) and the UF/DF ﬁlters.
Figure 2. Deterministic analysis results. (a) Cost of goods
breakdown by cost categories. (b) Cost of goods per
batch distributed per unit operation.
Table 1. Scenarios Used for Sensitivity Analysis
Scenarios
Variable Worst Base Best
Fermentation titer (g/L) 0.108 0.242 0.376
DSP yield (%) 94.7 95.8 96.9
Material cost (%) 125 0 225
Target output (kg/year) 12.8 25.6 51.2
Operator wage (location) US UK Mexico
Production operator $41,872 $32,935 $37,689
Production supervisor $52,337 $38,490 $37,689
Quality assurance $70,149 $56,176 $35,995
Quality control $39,101 $31,400 $35,995
Figure 1. Sequence of unit operations for the production of
Royalactin.
Each unit operation contains process time, volume-in and out,
yield and concentration of Royalactin.
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base case scenario target double or half. Finally, the operator
wage was adjusted to the prevailing pay rates in two coun-
tries that have a higher and lower salary than United King-
dom. The United States (US) was chosen because it has a
large number of biotechnological companies, including a
great number of suppliers. Mexico offer lower wages than
the other two countries. Each value on Table 1 was input
into the BioSolve model individually and the corresponding
CoG/g was recorded. Figure 3 show the results for the sensi-
tivity analysis.
From Figure 3, it can be seen that fermentation titer, tar-
get output, and the material costs are the top three parame-
ters affecting the CoG/g. It is important to note that when
fermentation titer was better than the base case scenario it
had less impact on the CoG/g compared to when it was
below the base case conditions. These results show that it is
important to design a strategy that achieves a CoG/g below
corresponding to the base case scenario. To this point the
insights have all been derived from individually modifying
each parameter, but during a real process, all parameters can
change simultaneously. It is also important to combine the
impact of uncertainty on these changes when the occur
simultaneously in order to assess the overall impact on likely
manufacturing scenarios.
Monte Carlo Analysis
A Monte Carlo analysis was performed in order to under-
stand how the CoG/g changes when the three key parameters
(fermentation titer, target output, and material costs) were
allowed to vary simultaneously, reﬂecting real manufacturing
behavior. BioSolve is not currently capable of performing
this type of analysis and therefore a program in Visual Basic
was coded to generate random values according to a triangu-
lar distribution. This type of probabilistic distribution is often
applied for bioprocess parameters with an expected mini-
mum, maximum, and most likely value.
22,29 The limits for
each function were taken from the values used for the sensi-
tivity analysis. A moving average (MA) was calculated after
each simulation run. Stable outcomes were achieved after
300 simulations runs and this was adopted as the standard
for the Monte Carlo analysis.
Of the three parameters to be analyzed, only titer can be
optimized experimentally. In order to analyze the effect of
optimizing this parameter, a certain base value needed to be
proposed. Based on literature,
17 one strategy to increase the
fermentation titer is by strain selection, which can enhance
production by threefold.
30 Alternatively, the incorporation of
different types of vector can increase titer. For example plas-
mids containing zeocin resistance (pPICZ A-C) have been
reported to yield a hyper-resistant strain of Pichia pastoris.
31
Increasing gene copy number can multiply production up to
7.5-fold.
32 If both strategies were to be applied simultane-
ously, an increase in fermentation titer up to 22.5-fold might
be theoretically expected. This analysis was used to provide
a new titer range: 5.4462.44 g/L. Monte Carlo analysis was
then performed for two scenarios, before and after titer opti-
mization. Figure 4 presents the results for the 300 simulation
runs for both scenarios.
Figure 4a shows that to achieve a low CoG/g it is neces-
sary to achieve high fermentation titer, high target output,
Figure 3. Cost of goods sensitivity to different parameters, ver-
tical axis crosses at the base scenario (CoG/
g5$843.00).
Figure 4. Monte Carlo Analysis results for cost of goods after
generating random values for titer, target output,
and material cost.
Cost of goods is represented by color variable. (a) CoG/g
before titer optimization (titer: 0.24260.134 g/L; CoG/g:
mean5$519.80, median5$821.58, range5$936.47). (b)
CoG/g after titer optimization (titer: 5.4462.44 g/L; CoG/g:
mean5$359.75, median5$347.23, range5$409.70).
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tions progresses from low titer, low target output and high
material costs (conditions that yield high CoG/g) to high
titer, high target output, and low material costs (conditions
necessary for reduced CoG/g). After optimization of titer
(Figure 4b), the simulation results change quite signiﬁcantly
with material costs having little inﬂuence and the dot density
goes from low target output and low titer (elevated CoG/g)
to high target output and high titer (low CoG/g) without
noticeable inﬂuence of material costs. It is important to note
that titer now has less effect than target output.
After obtaining the values for the CoG/g, a linear model
was calculated relating CoG/g as a function of titer, target
output and material costs (Table 2). It can be seen that after
optimization of the fermentation titer, material costs are no
longer statistically signiﬁcant (a50.01). This is consistent
with the dataset in Figure 4. For bioprocesses that achieve a
low level of production, the main focus is on the improve-
ment in the process parameters (e.g., fermentation titer).
Here is important to ensure that the titer is not low because
CoG/g increases rapidly. After optimization, the rank order
of the parameters changes (Table 3), and target output now
becomes the parameter that inﬂuences most the CoG/g.
Strikingly then the consequences of optimization of the bio-
process is to shift the manufacturing strategy, which a poten-
tial company might pursue, from being process-oriented to
product-oriented and a strategy that seeks to capture market
share needs to be implemented.
Conclusions
This paper sets out an economic analysis performed using
the commercial software, BioSolve, to analyze potential
manufacturing strategies for the production of Royalactin, an
interesting protein with valuable properties for potential use
as a dietary supplement. Contrasting the order of importance
of parameters before and after optimization provided insight
on how a company strategy might change in the light of dif-
ferent manufacturing scenarios. The need to conduct eco-
nomic analysis incorporating the impact of uncertainties by
performing Monte Carlo simulation runs is demonstrated,
such analysis allows the user to determine how the CoG/g
are distributed and for a range of possible scenarios to be
investigated which work to reduce the CoG/g. This study
provides a framework for future attempts to produce
Royalactin at scale. Analysis of process sensitivities was car-
ried out for two scenarios, before and after titer optimization.
Results show that work to improve the fermentation titer
needs to continue in order to obtain a low-cost product.
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